Clinical data and treatment outcome of patients.
| No. | Gender | Age, years | Course of disease | Primary site | HAART | Chemotherapy | Survival time | Outcome |
|---|---|---|---|---|---|---|---|---|
| 1 | Male | 46 | 3 months | Axillary nodes | AZT/3TC/NVP | VP/CODOXM/IVAC | >1 year | Partial remission |
| 2 | Female | 40 | 1 month | Stomach | d4T/3TC/NVP | R-CHOP/R-MINE/MINE | 1.5 years | Complete emission |
| 3 | Male | 56 | 1 year | Adrenal glands | d4T/3TC/NVP | CHOP | <1 year | Died of renal failure |
| 4 | Male | 57 | 2 months | Cervical lymph node | d4T/3TC/EFV | R-CHOP | No follow-up | Improved |
| 5 | Female | 30 | 20 days | Breast | Non | Abandoned treatment | 1 month | Died of lymphoma |
| 6 | Male | 30 | 1 month | Cervical lymph node | d4T/3TC/EFV | Recommended CHOP+/-E | No follow-up | Home treatment |
| 7 | Male | 28 | 1 month | Cervical lymph node | Non | Abandoned treatment | 2 months | Died of lymphoma |
| 8 | Male | 31 | 1 year | Encephalic | d4T/3TC/NVP | Dexamethasone | 2 months | Died of lymphoma |
| 9 | Male | 48 | 2 months | Axillary nodes | Non | CHOP | 2 months | Died of toxic shock |
| 10 | Male | 48 | 1 year | Colon | Non | CHOP | 6 months | Died of severe anemia |
d4T: stavudine; AZT: zidovudine; 3TC: lamivudine; NVP: nevirapine; EFV: stocrin. VP (vincristine + prednisone); CODOXM (cyclophosphamide + vincristine + pirarubicin+ cytarabine + methotrexate + calcium folinate); IVAC (cyclophosphamide + mesna + etoposide + cytarabine); CHOP (cyclophosphamide + adriamycin + vincristine + prednisone); R-CHOP (rituximab + cyclophosphamide + adriamycin + vincristine + prednisone); R-MINE (rituximab + ifosfamide + mitoxantrone + etoposide + prednisone); E: etoposide